English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

NMDA receptor (NMDAR) antibody encephalitis is the second most common autoimmune encephalitis after acute disseminated encephalomyelitis, presenting with a multistage clinical progression with prodromal signs, psychiatric abnormalities, reduced levels of consciousness, epileptic seizures, dyskinesias, and autonomic dysfunction.1 Pathogenic NMDAR autoantibodies downregulate NMDARs in cultured hippocampal neurons2 and after injection into the rat brain.3 Teratomas are common in adult women and are believed to trigger the antibody response against NMDARs by ectopically expressing neuronal antigens.1 Causal factors in tumor-negative patients are largely unknown. Recent studies showed that infectious encephalitides with herpes simplex virus (HSE) are associated with the generation of NMDAR antibodies4 and that antibodies cause immunotherapy-responsive relapsing symptoms post-HSE.5 It is unknown, however, whether further types of neuronal damage can trigger a secondary immune response leading to NMDAR encephalitis.

A case of inflammatory peripheral nerve destruction antedating anti-NMDA receptor encephalitis